CAPROCK Group Inc. Has $1.57 Million Position in Bristol-Myers Squibb Co (BMY)

CAPROCK Group Inc. lifted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,692 shares of the biopharmaceutical company’s stock after acquiring an additional 1,765 shares during the period. CAPROCK Group Inc.’s holdings in Bristol-Myers Squibb were worth $1,574,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. First Trust Advisors LP grew its position in Bristol-Myers Squibb by 10.7% in the 2nd quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after purchasing an additional 41,892 shares during the period. Toronto Dominion Bank grew its position in Bristol-Myers Squibb by 54.0% in the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after purchasing an additional 162,884 shares during the period. Oppenheimer & Co. Inc. grew its position in Bristol-Myers Squibb by 2.5% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after purchasing an additional 8,813 shares during the period. Mutual of America Capital Management LLC grew its position in Bristol-Myers Squibb by 1.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock worth $10,932,000 after purchasing an additional 3,833 shares during the period. Finally, Dividend Assets Capital LLC purchased a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth $737,000. 69.66% of the stock is owned by institutional investors.

Several research analysts have recently weighed in on BMY shares. Jefferies Group reiterated a “buy” rating and set a $66.00 price target (up previously from $63.00) on shares of Bristol-Myers Squibb in a research note on Thursday, August 24th. BMO Capital Markets reiterated a “sell” rating and set a $49.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, September 4th. Goldman Sachs Group reiterated a “buy” rating and set a $65.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price target on the stock. in a research note on Thursday, September 7th. Finally, Credit Suisse Group reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research note on Friday, September 8th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $64.42.

Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $61.50 on Friday. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market cap of $100,166.05, a price-to-earnings ratio of 20.68, a price-to-earnings-growth ratio of 2.32 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter last year, the firm earned $0.77 earnings per share. The business’s quarterly revenue was up 6.7% on a year-over-year basis. equities analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.60%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.

In related news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/12/22/caprock-group-inc-has-1-57-million-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit